The Tat protein of human immunodeficiency virus type 1 (HIV-1) is a regulatory protein which transactivates HIV-1 expression (7). However, Tat can be released from productively infected cells (8, 9) . Extracellular Tat is internalized by cells and localized in the nucleus (14, 16) , where it can affect a variety of cellular functions (3, 10, 13, 17, 18, 27, 31, 33) . For example, Tat can also act on neuronal cell membranes to produce neuronal excitation, elevation of intracellular calcium, and toxicity (20, 24, 28) . It also causes aggregation of neurons (25) . In astrocytes, extracellular Tat increases both NF-B binding and protein kinase C activity (6) . Tat also transactivates JC virus T antigen expression in astrocytes (5) . However, it remains to be determined if these actions are due to effects of Tat on the cell membrane or following internalization of Tat.
The ability of exogenous Tat to be taken up by cells has generated considerable interest due to the potential biotechnological applications whereby Tat can be used as a vehicle for delivering heterogeneous proteins and drugs that would otherwise not have access to the intracellular environment (11, 23) . In fact, substances conjugated to Tat have been shown to be localized in the nucleus (11) . Hence, it is important to determine the regions of Tat that are responsible for its uptake versus those that are responsible for its functional activities following internalization.
Tat is formed from two exons. The first exon encodes amino acids 1 to 72 (Tat , and the second is of variable length, encoding another 14 to 32 amino acids. Tat 1-72 is sufficient for transactivation, which is regulated by the basic region of Tat between amino acid residues 49 and 57 (1, 15, 16, 30) . The biological function of the C-terminal region encoded by the second exon is still unclear. However, the C-terminal region has an integrin receptor binding sequence (Arg-Gly-Asp) (3, 32) . In this study, we define the regions of Tat that regulate its uptake into brain cells.
Uptake of Tat 1-86 and Tat 1-72 . Human fetal brain tissue (gestational age, 13 to 16 weeks) was obtained with written consent from women undergoing elective termination of pregnancy and with approval of the University of Manitoba Human Ethics Committee. Human fetal astrocyte and neuron cultures were prepared as described previously (19, 20) . Purity of astrocytes (Ͼ95%) and neurons (Ͼ70%) was determined by immunostaining for glial fibrillary acidic protein and microtubule-associated protein 2, respectively. Prior to the binding assay, the cells were plated into 24-well plates and grown to 100% confluence (5 ϫ 10 5 cells per well). The Tat gene encoding the first 72 amino acids (first exon) was inserted into an Escherichia coli vector, PinPoint Xa-2 (Promega), expressed as a fusion protein. Tat 1-72 was enzymatically cleaved from the fusion protein and purified as described previously (6) . The Tat protein was Ͼ95% pure as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie blue staining. The purified product was further confirmed by Western blot analysis using polyclonal antisera to Tat (AIDS repository, National Institutes of Health). Recombinant HIV-1 BRU Tat 1-86 was obtained from Repligen and was Ͼ98% pure. Purified Tat or Tat 1-72 was labeled with Na 125 I by using Iodo-beads (Pierce). The labeled protein was separated from free 125 I with a PD-10 column (Pharmacia). The specific activity of 125 I-Tat was 2.4 ϫ 10 4 cpm/ng. Cellular uptake assays of 125 I-Tat were performed as previously described (14, 20) . Briefly, cells were incubated with various concentrations of 125 I-Tat 1-86 or 125 I-Tat 1-72 (2 to 64 nM) in 0.2 ml of binding medium (Dulbecco's modified Eagle medium [DMEM] and 0.1% bovine serum albumin) at room temperature for 30 min to 4 h. The cells were washed in ice-cold DMEM and treated with 0.2 ml of trypsin-EDTA (GIBCO BRL) for 10 min at 37ЊC. The cells were centrifuged, and supernatant was removed as a membrane fraction. The cell pellet was washed twice in DMEM with 10% fetal bovine serum. The nuclear and cytoplasmic fractions were isolated by lysis in 0.2 ml of 0.5% Nonidet P-40 (vol/vol) as described previously (2) . The fractions were counted in a gamma counter. Uptake of both 125 I-Tat 1-86 and 125 I-Tat 1-72 was time and dose dependent (Fig. 1) . However, the uptake of 125 ITat 1-72 was much lower than that of 125 I-Tat 1-86 (0.08 Ϯ 0.01 nM versus 0.42 Ϯ 0.009 nM at 4 h; P Ͻ 0.01) (Fig. 1A) . At the maximal concentration (64 nM) of 125 I-Tat 1-86 or 125 I-Tat 1-72 tested, the uptake of Tat could not be saturated (Fig. 1B) .
Further, Ͼ90% of internalized 125 I-Tat 1-86 was localized in the nucleus while the cytoplasmic fraction represented only Ͻ10% in the astrocytes (Fig. 1C) . To further confirm the nuclear localization and the fate of Tat within the nucleus, nuclear fractions were prepared from 125 I- Tat To further determine the specificity of Tat uptake, immunoabsorption of Tat was performed as described previously (20) . Briefly, a 1:100 dilution of rabbit anti-Tat serum or normal rabbit serum was bound to protein A-Sepharose (Pharmacia) and incubated with 125 I-Tat for 1 h at room temperature followed by centrifugation. The supernatants were collected and used for Tat uptake assays. The uptake of 125 I-Tat 1-86 or 125 I-Tat 1-72 treated with normal rabbit sera was normalized to 100%. As shown in Fig. 3 , cellular uptake of 125 I-Tat 1-86 and 125 I-Tat 1-72 treated with anti-Tat sera was decreased by 79% Ϯ 11% and 78% Ϯ 3%, respectively, demonstrating that the uptake of Tat was specific.
Competition of Tat (Fig. 4B) .
Role of integrin binding on uptake of Tat (Fig. 4C) . Conversely, when astrocytes were treated similarly with 125 I-Tat in the presence of Tat , a fivefold enhancement of Tat uptake was observed (P Ͻ 0.01) while Tat 48-86 had no effect on 125 I-Tat 1-72 uptake by astrocytes (Fig.  4D) . The cells were also pretreated with polyclonal antisera to [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] and Tat 18-32 also produced a 10-fold and a 2-fold enhancement of 125 I-Tat 1-72 uptake, respectively, while the remaining 15-mer peptides had no significant effect (Fig. 5A) . Similarly, Tat 72-86 , which sup- plements the deleted region of the second exon, had no effect on 125 I-Tat 1-72 uptake (Fig. 5A ).
To determine if internalized Tat 1-72 retains its functional properties, transactivation of the HIV long terminal repeat (LTR) was determined in HL3T1 cells containing the LTRchloramphenicol acetyltransferase (CAT) (AIDS Repository, National Institutes of Health) treated with 0.5 M Tat 1-72 without scrape-loading in the presence or absence of 6 M Tat 1-15 , Tat [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , or Tat 72-86 . The Tat transactivation assay was performed as previously described (12, 14) , and CAT activity was measured by a simple phase extraction assay (29) . As shown in Fig. 5B , Tat 28-42 produced a ninefold increase in Tat 1-72 -induced LTR transactivation while Tat [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] or Tat 72-86 had no effect. Tat 28-42 alone did not show any transactivation activity.
Not only is understanding the precise mechanisms underlying the internalization of extracellular Tat important in determining its role in regulating viral and host function, but this phenomenon could also potentially be exploited to deliver heterologous proteins or drugs into cells. We demonstrate here that both full-length Tat and to a lesser degree Tat 1-72 are internalized by brain cells and that following entry, they are predominantly localized in the nucleus. Consistent with previous observations that Tat 1-86 uptake in lymphoid and monocytoid cells could be inhibited by polyanions such as heparin or dextran sulfate (21), we found that Tat 1-72 uptake in astrocytes could also be blocked by dextran sulfate, suggesting that internalization of Tat is charge dependent. We demonstrate that uptake of 125 I-Tat 1-86 and 125 I-Tat 1-72 by human fetal astrocytes was competitively inhibited dose dependently by an excess of unlabeled Tat , suggesting that uptake of 125 I-Tat 1-72 is receptor mediated.
Transactivation of HIV-2 Tat requires full-length protein (26) , while the HIV-1 Tat 1-72 has the same efficiency for transactivation as HIV-1 Tat 1-86 (16) . The role of the C-terminal region formed by the second exon of the tat gene in HIV-1 infection was not previously determined. We observed that even though both Tat 1-86 and Tat 1-72 could be internalized by several cell types, Tat 1-86 internalization was up to 10 times more efficient than that by Tat , suggesting that the region encoded by the second exon is important in mediating Tat internalization. However, Tat 1-72 uptake was not affected by coincubating with peptides including the second exon (Tat [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] or Tat 48-86 ). Thus, peptide bond linkage of the peptides encoded by the two exons is essential for the efficient uptake of Tat. This linkage most likely influences the tertiary configuration of the molecule. The importance of the tertiary configuration for Tat uptake is further supported by the results of Bonifaci et al., which demonstrate that the Tat molecule unfolds before entering the cells (4). However, the peptide encoded by the second exon is not exclusively involved in Tat uptake since significant uptake of Tat 1-72 was also observed.
Tat is highly conserved between different strains of HIV-1. However, the second exon shows heterogeneity in the amino acid sequence and is of variable length. Since this region is a major determinant of Tat uptake into the cell, it could play an important role in regulating strain-to-strain variability of (32) . However, it is unlikely that binding of Tat to these integrin receptors influences Tat uptake since Tat 49-86 containing the RGD sequence, Tat containing the basic domain, or antisera to integrins ␣ 5 ␤ 1 , ␣ v ␤ 3 , or ␣ v ␤ 5 could not inhibit Tat uptake.
Our results show that Tat 28-42 also greatly increased Tat 1-72 uptake and transactivation. This peptide contains only four basic amino acids and increased Tat uptake by 35-fold, while Tat 38-52 , which contains five basic amino acids had no significant effect on Tat uptake, indicating that a mechanism of enhancement other than positive charge dependence might also be involved.
The phenomenon by which one protein facilitates the internalization of another protein has also been observed in anthrax toxins. The protective antigen of anthrax toxin can form ionconductive channels in biological membranes and convey the edema factor and lethal factor of the toxin into the cytoplasm by inducing changes in the membrane permeability (22) . Presumably, the Tat peptides can use a similar mechanism to facilitate the internalization of Tat protein.
We thus conclude that the cellular uptake of Tat (i) is determined by the tertiary configuration of the molecule, (ii) is dependent upon the C-terminal region and the basic region of Tat, and (iii) is perhaps independent of integrin binding. Further, Tat uptake can perhaps be enhanced by an autologous peptide through yet-unknown mechanisms.
